|Indication||Platform||Concept||Pre-Clinical||Phase I/IIA||Phase IIB/III|
|Adjunctive treatment for long bone fractures||Bone Healing Accelerant|
|Adjunctive treatment for total joint replacement||Bone Healing Accelerant|
|Enhancer & Extender for DBM (demineralized bone) spine||Bone Healing Accelerant|
|Reduction in surgical site infection for colorectal surgery||Tissue Healing Accelerant|
|Reduction in surgical site infection for sternotomy||Tissue Healing Accelerant|
|Reducton in surgical site infection for C-Section/hysterectomy||Tissue Healing Accelerant|
Allogenic pooled plasma utilized in Carmell’s processing is screened and processed by an FDA registered and AABB accredited U.S. blood bank and is therefore considered free of known blood-borne pathogens. It is then re-screened using sensitive nucleic acid amplification technology (NAT), and additional steps are taken to remove any new viral contaminants that conventional screening may miss. The final product is also terminally sterilized after packaging, meeting FDA’s and EMA’s stringent requirements to ensure safety.